-+ 0.00%
-+ 0.00%
-+ 0.00%

NuCana Announces Grant Of Composition-Of-Matter Patent For NUC-7738 In The U.S.

Benzinga·09/25/2024 20:03:41
Listen to the news

NuCana plc (NASDAQ:NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738's composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO Congress 2024 earlier this month.